Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Ferring claims degarelix results in significant reduction in testosterone levels

Ferring claims degarelix results in significant reduction in testosterone levels

30th June 2008

Phase III study results have revealed that the investigational GnRH blocker, degarelix, produced significant reduction in testosterone1,2 levels within three days in over 96 per cent of study patients.

The data reveals that degarelix, a prostate cancer treatment, produced an effect on testosterone levels which was close to the immediate effect achieved with surgery.

During the study, monthly administration of degarelix was compared with monthly administration of LHRH agonist leuprorelin’s 7.5 mg in a 12-month, randomised, open-label parallel-group study in prostate cancer patients.

Ferring Pharmaceuticals claims degarelix suppressed serum testosterone and prostate specific antigen significantly faster.

The company states that degarelix was also able to sustain these low levels for the entire study.

John Anderson, consultant urological surgeon at the Royal Hallamshire Hospital in Sheffield, said: “Our goal is always to have a fast and sustained reduction in testosterone levels.”

According to Ferring, all studies have found degarelix to be safe, well-tolerated and with no evidence of allergic reactions.

The company submitted applications in Europe and the US for the marketing authorisation of degarelix back in February.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.